PT-141 vs Kisspeptin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Bremelanotide, Vyleesi
PT-141, generic name bremelanotide and sold as Vyleesi, is a melanocortin peptide and a cyclic analog of alpha-MSH that works in the brain to boost sexual desire. It is genuinely FDA approved: in June 2019 it became the first on-demand treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label for low libido and erectile dysfunction in men.
Also: Kisspeptin-10, Kisspeptin-54
Kisspeptin is the master switch that tells your brain to start reproduction. It is a family of peptides (the full length is kisspeptin-54, with shorter active fragments KP-14, KP-13, and KP-10) made from the KISS1 gene, and it acts as the upstream trigger for the entire reproductive hormone cascade. It is not an approved drug, but it has been tested in real human trials for fertility, hypothalamic amenorrhea, and male hypogonadism, with promising early results.
Key Comparison Insights
- PT-141 is FDA approved, while Kisspeptin remains in research stages.
- PT-141 is categorized as Sexual Health, while Kisspeptin is Hormonal.
- PT-141 has stronger research evidence (FDA Approved) compared to Kisspeptin (Human Trials).
Detailed Comparison
| Attribute | PT-141 | Kisspeptin |
|---|---|---|
| Category | Sexual Health | Hormonal |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Bremelanotide activates melanocortin receptors in the brain, mainly MC4R with some MC3R activity, in the hypothalamus. Unlike PDE5 drugs such as sildenafil that work on blood flow in the genitals, PT-141 acts centrally on the neural circuits that generate sexual desire and arousal, so its effect does not depend on hormone levels or direct physical stimulation. That same MC4R activity is why nausea is its most common side effect, and why it can transiently raise blood pressure and lower heart rate, which shaped its dosing limits. | Kisspeptin binds the receptor KISS1R, also called GPR54, on GnRH neurons in the hypothalamus. That binding activates phospholipase C and the inositol-triphosphate and diacylglycerol second messengers, which drives GnRH release. GnRH then signals the pituitary to pump out LH and FSH, the gonadotropins that run the ovaries and testes. This is why kisspeptin sits at the very top of the chain: a small nudge here cascades into a large downstream hormonal response. Inactivating mutations in KISS1 or KISS1R cause failure of puberty and infertility, while activating mutations cause precocious puberty, which is how scientists pinned down that this signal is essential, not optional. |
| Common Dosing | 1.75 mg as needed As needed, at least 45 min before activity | 100-200 mcg subcutaneously once daily Once daily or every other day |
| Administration | Subcutaneous injection (autoinjector available) | IV (research), subcutaneous (investigational) |
| Typical Duration | As needed, at least 45 min before activity | Variable by protocol |
| Best Time to Take | 1-2 hours before sexual activity | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | PT-141 has some of the strongest evidence of any peptide on the gray market because it went through a full FDA program. The pivotal data come from the two identical phase 3 RECONNECT trials by Kingsberg and colleagues, published in Obstetrics and Gynecology in 2019, which randomized 1,267 premenopausal women with HSDD to 1.75 mg subcutaneous bremelanotide as needed or placebo. Both trials showed statistically significant improvements in sexual desire and in distress over low desire (both P less than 0.001), though the real-world benefit is modest: the effect size on desire scores was roughly 0.3 to 0.6, and the gain in satisfying sexual events over placebo was small. Nausea affected around 40 percent of women and was the leading reason people stopped, and dosing is capped at eight doses per month. Use in men for libido or erectile dysfunction is off-label and far less rigorously studied than the approved female HSDD indication. | Kisspeptin has more genuine human data than most peptides sold in this space, because it is studied as a real fertility tool, not a supplement. In women with hypothalamic amenorrhea, subcutaneous kisspeptin-54 raised LH around 10-fold and FSH about 2.5-fold back into normal range, and infusion protocols restored LH pulse frequency. A landmark IVF application used kisspeptin-54 to trigger oocyte maturation, leading to a reported live term birth, and it is being explored as a gentler trigger that may lower ovarian hyperstimulation risk. In hypogonadal men, kisspeptin-10 infusion increased LH roughly 5-fold and pushed testosterone into the normal range. That said, most of this comes from small academic studies and infusion protocols at specialist centers, not large multi-center phase 3 trials, and no kisspeptin product is FDA approved. The injectable peptide sold to consumers is not the same as a validated clinical fertility treatment, and short-term hormone shifts do not equal long-term safety data. |
Frequently Asked Questions: PT-141 vs Kisspeptin
What is the difference between PT-141 and Kisspeptin?
PT-141 is a sexual health peptide that pt-141, generic name bremelanotide and sold as vyleesi, is a melanocortin peptide and a cyclic analog of alpha-msh that works in the brain to boost sexual desire. it is genuinely fda approved: in june 2019 it became the first on-demand treatment for acquired, generalized hypoactive sexual desire disorder (hsdd) in premenopausal women. it is also used off-label for low libido and erectile dysfunction in men. Kisspeptin is a hormonal peptide that kisspeptin is the master switch that tells your brain to start reproduction. it is a family of peptides (the full length is kisspeptin-54, with shorter active fragments kp-14, kp-13, and kp-10) made from the kiss1 gene, and it acts as the upstream trigger for the entire reproductive hormone cascade. it is not an approved drug, but it has been tested in real human trials for fertility, hypothalamic amenorrhea, and male hypogonadism, with promising early results. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PT-141 or Kisspeptin?
Neither is universally "better" - the choice depends on your specific goals. PT-141 is typically used for sexual health purposes, while Kisspeptin is used for hormonal. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PT-141 and Kisspeptin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PT-141 and Kisspeptin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.